CPB
NASDAQ · Food Products
The Campbell'S Company
$21.21
+0.81 (+3.97%)
CPB News30 articles
Soy Allergen Omission Triggers Power Plate Meals Frozen Meatloaf Recall
Power Plate Meals LLC recalls 5,795 pounds of frozen meatloaf with garlic mashed potatoes for undeclared soy. Products shipped to MN, ND, SD; no adverse reactions reported.
Campbell's Set for S&P 500 Exit as Small-Cap Shift Looms
Campbell's (CPB) drops 7.3% before its index rebalance from S&P 500 to S&P SmallCap 600. The stock yields 7.4%, but guidance signals a 23-26% EPS drop.
Campbell Soup Edges Higher Despite S&P 500 Removal and Soft Sales
Campbell's (CPB) shares rose slightly premarket after adjusted profit topped expectations, though quarterly sales fell 4% and the stock faces removal from the S&P 500 on June 22.
Marvell Technology Surges on S&P 500 Addition Announcement
Marvell Technology surged 7% premarket after being added to the S&P 500, with shares at $282.50. The move underscores its AI-driven revenue and raised outlooks.
Campbell Soup Set for S&P 500 Exit Ahead of Weak Earnings Report
Campbell Soup (CPB) exits the S&P 500 on June 22, moving to the SmallCap 600, as analysts forecast lower Q3 sales and earnings. The stock rose 2.7% last week despite broader market losses.
Flex Set to Join S&P 500; Index Rebalancing Adds Complexity
Flex (FLEX) will join the S&P 500 on June 22, replacing Campbell's. The stock fell 4.8% Friday but gained 1.5% after hours. AI data-center focus and planned spinoff add interest.
Flex Gains S&P 500 Entry Amid AI Power Unit Growth, Shares Slide in Tech Rout
Flex (FLEX) is set to join the S&P 500 on June 22, drawing attention to its surging AI data-center power unit and planned spin-off, though shares dropped 4.8% in a tech selloff.
Campbell's Bounces Near Low, Q3 Report Looms
Campbell's shares edged up 2.6% to $20.58, rebounding from a 52-week low. The next catalyst is fiscal Q3 earnings on June 8, with analysts cautious.
Conagra Brands Faces Dividend Risk as Shares Hit New Lows
Conagra Brands' stock fell to $14.17, near a 52-week low, as BofA warns its dividend is at risk. The company faces inflation, tariffs, and a leadership change.
Hershey's $1.7B Rally on Cocoa Margin Hopes Faces Weather Risk
Hershey shares surged 4.9% to $179.27, adding $1.7 billion in value, as investors bet on margin recovery from lower cocoa costs. However, rising cocoa prices due to Ivory Coast weather risks threaten the rebound.
Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering
Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.
Catheter Precision Surges 34.5% Premarket on Patent News and Resale Filing
Catheter Precision (VTAK) surged 34.5% premarket following a flurry of announcements including new patents, a sports partnership, and a resale share filing for 68.1 million shares.
Nexentis Shares Surge 156% on AI Drug Discovery Pact, Then Retreat
Nexentis shares skyrocketed 156% after announcing an AI drug discovery deal and a $2.9 million stock-and-warrant offering, but declined 26% in after-hours trading amid dilution concerns.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
PG&E Outages Hit 9,000 Across Three Counties Amid Fire Weather
PG&E outages affected over 9,000 customers in Monterey, Clovis, and Shasta County amid storms and fire weather, underscoring utility challenges in maintaining reliability during peak summer demand.
Wolfspeed Surges 18% Then Files Share Resale, Testing AI Chip Rally
Wolfspeed shares surged 18% before filing to register 24 million shares for resale, raising dilution concerns. The silicon carbide chipmaker's AI-driven rally faces a test when markets reopen.
CervoMed Shares Surge on Patent News, Then Retreat After $10M Stock Offering
CervoMed shares surged to $7.75 after a U.S. patent allowance for neflamapimod in pure DLB, but gave back most gains after announcing a $10 million stock offering at $4 per share. The stock last traded at $4.14, up 8.7%.
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
The Agency Expands in Central America with New Belize Office in Placencia
The Agency has opened its first Belize office in Placencia, expanding its Central America network. The move aims to capture rising foreign buyer interest, though past fraud cases remain a warning for investors.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
Outlook Therapeutics Surges on FDA Review of Wet AMD Treatment
Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, setting a PDUFA target date of July 29, 2026.
Bitmine Stock Rises as Ethereum Holdings Hit 5.62 Million ETH
Bitmine Immersion Technologies (BMNR) jumped 6.21% to $17.11 after revealing its Ethereum treasury reached 5,620,754 ETH, representing 4.66% of total supply.
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
AmEx to Acquire TheFork from TripAdvisor for $700M, Expanding Dining Network
American Express will acquire TheFork from TripAdvisor for $700 million in cash, expanding its dining network to 75,000 bookable venues and allowing TripAdvisor to focus on its Experiences segment.
BitMine's Ethereum Holdings Surge to 5.62M ETH, Stock Climbs Ahead of Preferred Debut
BitMine Immersion Technologies shares jumped 6.7% to $17.19 after revealing a massive Ethereum treasury of 5.62 million ETH, ahead of its Series A preferred stock listing on the NYSE.
Ethereum Rebound Watch: BitMine Accumulates 5.62M ETH, Lee's $22K Target in Focus
BitMine boosts Ethereum stash to 5.62M ETH, reigniting debate over Tom Lee's $22,000 target as ETH trades near $1,775.
Cuban Dumps Bitcoin, Calls It 'Lost the Plot' as Price Tops $64K
Mark Cuban says Bitcoin has lost its purpose as a hedge, revealing he sold most of his holdings before recent conflicts, even as BTC briefly topped $64,000.
Bitmine Stock Climbs After Preferred Share Sale, Ethereum Accumulation
Bitmine Immersion Technologies shares gained 5.6% to $16.52 after closing a $273.8M preferred stock sale, with proceeds likely for Ethereum purchases and staking. The firm now holds 5.54M ETH, or 4.59% of total supply.